|Bid||247.15 x 1100|
|Ask||251.38 x 1000|
|Day's Range||236.72 - 248.11|
|52 Week Range||123.11 - 255.38|
|PE Ratio (TTM)||50.18|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||253.00|
CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins sold 34,500 shares of LGND on 08/17/2018 at an average price of $241.96 a share.
Investors looking for fast-growing stocks in an expensive market might want to follow the lead of Mike Balkin and Ward Sexton, managers of the superstar William Blair Small Cap Growth fund, which has outpaced 94% of small-cap growth funds tracked by Morningstar.
Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Ligand Pharmaceuticals Incorporated (LGND) and Vernalis plc (VER.L) announce that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis through a UK scheme of arrangement conditional on approval by the Vernalis shareholders. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations. Under the terms of the proposed UK scheme of arrangement, Ligand would pay Vernalis shareholders £0.062 per share in cash, valuing Vernalis at approximately £32.8 million, equivalent to approximately $43 million.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) beat top-line, bottom-line and royalties estimates in its second-quarter report, and it boosted annual guidance in the process. But one analyst sees limited ...
Just up the road from where Nobel Prize winner Eugene Fama developed his efficient-market hypothesis, Mike Balkin and Ward Sexton are all about finding inefficiencies. Like Fama, the Chicago-based managers favor smaller firms, but their aim is to discover growing companies that the market doesn’t yet see or understand—a firm with an energy-industry technology with much wider applications, for instance, or a retailer of cowboy and work boots whose public debut coincided with the oil patch’s double-digit collapse in prices. “We’re not afraid to be contrarian at times,” says Balkin, 59, who helped launch the $668 million William Blair Small Cap Growth fund (WBSNX) in 1999.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...
After hours: Etsy earnings missed, but the internet retailer's stock signaled a breakout. Weight Watchers, Twilio, Ligand, Turtle Beach and Five9 were other top stocks moving on earnings.
Ligand Pharmaceuticals reported adjusted profit of $2.59 per share on $90 million in sales for its second quarter.
Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 6) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...
Ligand (LGND) delivered earnings and revenue surprises of 178.49% and 48.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had net income of $2.99. Earnings, adjusted for one-time gains and costs, came to $2.59 per share. The drugmaker posted revenue of $90 million ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 ...
The bonds pay 0.75 percent interest and are due in 2019, and each $1,000 bond can be converted into 13.3251 shares of Ligand stock, a conversion price of about $75.05 per share. Ligand’s stock closed yesterday at $215.37, so the bonds are very in-the-money, and if you bought them you did very well: Each $1,000 bond is convertible into about $2,870 worth of stock. Like, you take the conversion rate and multiply it by the stock price, and you give bondholders that much cash.